Kirollos M M, McDermott S, Bradbrook R A
Urology Department, Torbay Hospital, South Devon Health Care Trust, UK.
Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(4):228-35. doi: 10.1007/BF01901609.
Despite the diversity of the available markers, none is truly specific to transitional epithelium, let alone its tumors. Some of the markers used, such as hCG and CEA, are far better known in other fields and seem to be expressed in only a minority of urothelial tumors. The majority of the available markers are tumor associated and should perhaps be considered as by-products of the process of malignancy in the urinary tract. Newer tests which are simple, rapid and easy to use have a practical advantage. These are currently the Bard BTA, BTA Stat and Aura-Tek FDP tests. So far, these markers have achieved only an arguable and marginal role in daily clinical practice, challenging the role of cytology and helping decide the type of cystoscopy. A more substantial role awaits a test with higher and more consistent sensitivity and specificity, together with the capability to provide independent diagnostic and/or prognostic information. In this part of the review we examine the literature view of the above-mentioned tests, as well as other new and some older tests such as blood group-related antigens, Lewis antigen, cytokeratins and others.
尽管现有标志物多种多样,但没有一种是真正特异于移行上皮的,更不用说其肿瘤了。所使用的一些标志物,如人绒毛膜促性腺激素(hCG)和癌胚抗原(CEA),在其他领域更为人熟知,似乎仅在少数尿路上皮肿瘤中表达。大多数现有标志物与肿瘤相关,或许应被视为尿路恶性肿瘤过程的副产物。操作简单、快速且易于使用的新型检测方法具有实际优势。目前有Bard BTA、BTA Stat和Aura-Tek FDP检测。到目前为止,这些标志物在日常临床实践中仅发挥了有争议的边缘作用,对细胞学的作用提出了挑战,并有助于决定膀胱镜检查的类型。要发挥更重要的作用,还需一种具有更高且更一致的敏感性和特异性,并能够提供独立诊断和/或预后信息的检测方法。在本综述的这一部分,我们将审视上述检测方法以及其他新的和一些较旧的检测方法,如血型相关抗原、刘易斯抗原、细胞角蛋白等的文献观点。